Head-To-Head Contrast: enGene (NASDAQ:ENGN) & Immunovant (NASDAQ:IMVT)

Immunovant (NASDAQ:IMVT) and enGene (NASDAQ:ENGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Institutional and Insider Ownership

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 5.9% of Immunovant shares are owned by company insiders. Comparatively, 13.7% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for Immunovant and enGene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	0	0	11	0	3.00
enGene	0	0	9	1	3.10

Immunovant presently has a consensus price target of $48.10, suggesting a potential upside of 70.57%. enGene has a consensus price target of $30.38, suggesting a potential upside of 251.16%. Given enGene’s stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than Immunovant.

Profitability

This table compares Immunovant and enGene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-56.40%	-52.03%
enGene	N/A	-66.38%	-56.00%

Risk & Volatility

Immunovant has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.76, indicating that its stock price is 176% less volatile than the S&P 500.

Earnings & Valuation

This table compares Immunovant and enGene”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$259.34 million	($2.22)	-12.70
enGene	N/A	N/A	-$99.92 million	N/A	N/A

Summary

enGene beats Immunovant on 6 of the 10 factors compared between the two stocks.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.